Browsing by Author "Demir, Hacer"
Now showing items 1-3 of 3
-
Comparison of survival with somatostatin analog and chemotherapy and prognostic factors for treatment in 165 advanced neuroendocrine tumor patients with Ki-67 20% or less
Ozaslan, Ersin; Karaca, Halit; Koca, Sinan; Sevinc, Alper; Hacioglu, Bekir; Ozkan, Metin; Ozcelik, Melike; Duran, Ayse O.; Hacibekiroglu, Ilhan; Yildiz, Yasar; Tanriverdi, Ozgur; Menekse, Serkan; Aksoy, Asude; Bozkurt, Oktay; Urvay, Semiha; Uysal, Mukremin; Demir, Hacer; Ciltas, Aydin; Dane, Faysal (LIPPINCOTT WILLIAMS & WILKINS, 2017)The objectives of this study were to compare progression-free survival (PFS) with somatostatin analog (SSA) versus chemotherapy (CTx) in first-line therapy and to determine the patient group in which these treatments were ... -
Efficacy and safety of cetuximab plus FOLFOX in second-line and third-line therapy in metastatic colorectal cancer
Ozaslan, Ersin; Topaloglu, Ulas Serkan; Inanc, Mevlude; Erdem, Umut Gokmen; Demir, Hacer; Arpaci, Erkan; Seker, Mehmet Metin; Karaaga, Mustafa; Kiziltepe, Melih; Eker, Baki; Ozkan, Metin (IMPRIMATUR PUBLICATIONS, 2017)Purpose: To evaluate the efficacy and adverse events with cetuximab plus FOLFOX administered as second- and third-line therapy in metastatic colorectal cancer (mCRC) patients. Methods: IPatients were administered cetuximab ... -
EGFR-targeted treatments in patients with metastatic colorectal cancer: Experience of panitumumab.
Gumus, Mahmut; Geredeli, Caglayan; Ucar, Mahmut; Kaya, Serap; Demir, Hacer; Unal, Olcun Umit; Degirmenci, Mustafa; Dogu, Gamze Gokoz; Turan, Nedim; Yildirim, Nilgun; Basal, Fatma Bugdayci; Arpaci, Erkan; Karaagac, Mustafa; Harputluoglu, Hakan; Turk, Had Mehmet; Dane, Faysal; Ozkan, Metin (AMER SOC CLINICAL ONCOLOGY, 2017)…
